Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06847724 · ClinicalTrials.gov registry record · Phase 3
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Sandoz.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
- 20
- Study locations
NCT06847724: Recruiting Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Sandoz.
NCT06847724 is a Phase 3 study of Relapsing Multiple Sclerosis that is actively recruiting participants, run by Sandoz. The registered enrollment target is 175 participants, below the 2,162-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06847724, a Phase 3 study of Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by Sandoz.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R). The main questions it aims to answer are: * Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)? * Does have CYB704 the same treatment effect and side effects as the reference product? Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will: * Take drug CYB704 or Ocrevus (Ocrevus-US and Ocrevus-EU) * Visit the clinic for at least 15 treatment visits, checkups and tests * Will undergo regular magnetic resonance imaging (MRI) examinations
Primary Outcome
Demonstrate similar PK between Ocrevus and CYB704
Conditions Studied
Interventions
- BIOLOGICAL CYB704
- BIOLOGICAL Ocrevus-EU
- BIOLOGICAL Ocrevus-US
Study Locations (20)
Other
- Sandoz Investigational Site - Banja Luka
- Sandoz Investigational Site - Bihać
- Sandoz Investigational Site 2 - Sarajevo
- Sandoz Investigational Site - Sarajevo
- Sandoz Investigational Site - Pleven
- Sandoz Investigational Site 2 - Plovdiv
- Sandoz Investigational Site - Plovdiv
- Sandoz Investigational Site 2 - Sofia
- Sandoz Investigational Site 3 - Sofia
- Sandoz Investigational Site 4 - Sofia
- Sandoz Investigational Site 5 - Sofia
- Sandoz Investigational Site - Sofia
- Sandoz Investigational Site - Varaždin
- Sandoz Investigational Site - Zagreb
- Sandoz Investigational Site - Rustavi
- Sandoz Investigational Site 2 - Tbilisi
- Sandoz Investigational Site 3 - Tbilisi
- Sandoz Investigational Site 4 - Tbilisi
Florida
- Sandoz Investigational Site - Maitland
- Sandoz Investigational Site - Ormond Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2029-10-14 |
| Phase | Phase 3 |
What NCT06847724 shows while recruiting
NCT06847724 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 2,162-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which CYB704 is the first listed.
NCT06847724 names 20 study sites across 2 states, led by Other, Florida.
Frequently Asked Questions
What is clinical trial NCT06847724 about?
NCT06847724 is a clinical study titled "Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis". The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R). The main questions it aims to answer are: * Is CYB704 distributed in the body in the same way as the reference produc...
What is the current status of trial NCT06847724?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2025-06-10. Estimated completion is 2029-10-14.
What conditions does trial NCT06847724 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06847724?
The interventions under investigation include: CYB704 (BIOLOGICAL), Ocrevus-EU (BIOLOGICAL), Ocrevus-US (BIOLOGICAL).
Who is sponsoring clinical trial NCT06847724?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06847724 being conducted?
This trial has 20 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06847724's enrollment target sits among peer trials
175 16th of 23 higher than 8 of 23 other Relapsing Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
RECRUITING · Phase 3
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI